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Abstract
To elucidate the regulation of glucocorticoid receptor (GR) signaling under pro-asthmatic conditions, cultured human
airway smooth muscle (HASM) cells were treated with proinflammatory cytokines or GR ligands alone and in combination,
and then examined for induced changes in ligand-dependent and -independent GR activation and downstream signaling
events. Ligand stimulation with either cortisone or dexamethsone (DEX) acutely elicited GR translocation to the nucleus and,
comparably, ligand-independent stimulation either with the Th2 cytokine, IL-13, or the pleiotropic cytokine combination, IL-
1b/TNFa, also acutely evoked GR translocation. The latter response was potentiated by combined exposure of cells to GR
ligand and cytokine. Similarly, treatment with either DEX or IL-13 alone induced GR phosphorylation at its serine-211 residue
(GRSer211), denoting its activated state, and combined treatment with DEX+IL-13 elicited heightened and sustained GRSer211
phosphorylation. Interestingly, the above ligand-independent GR responses to IL-13 alone were not associated with
downstream GR binding to its consensus DNA sequence or GR transactivation, whereas both DEX-induced GR:DNA binding
and transcriptional activity were significantly heightened in the presence of IL-13, coupled to increased recruitment of the
transcriptional co-factor, MED14. The stimulated GR signaling responses to DEX were prevented in IL-13-exposed cells
wherein GRSer211 phosphorylation was suppressed either by transfection with specific serine phosphorylation-deficient
mutant GRs or treatment with inhibitors of the MAPKs, ERK1/2 and JNK. Collectively, these novel data highlight a
heretofore-unidentified homeostatic mechanism in HASM cells that involves pro-asthmatic cytokine-driven, MAPK-
mediated, non-ligand-dependent GR activation that confers heightened glucocorticoid ligand-stimulated GR signaling.
These findings raise the consideration that perturbations in this homeostatic cytokine-driven GR signaling mechanism may
be responsible, at least in part, for the insensirtivity to glucocorticoid therapy that is commonly seen in individuals with
severe asthma.
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Introduction
Due to their potent immunosuppressive and anti-inflammatory
properties, glucocorticoids (GCs) are commonly used as the
primary treatment for many autoimmune, proinflammatory and
allergic diseases. GCs act by binding to the intracellular
glucocorticoid receptor (GR), thereby enabling it to dissociate
from its chaperone proteins, become phosphorylated, and
translocate as a homodimer to the nucleus. The intra-nuclear
ligand-activated GR can then initiate gene transactivation by
directly interacting with specific DNA sequences, the glucocorti-
coid response elements (GREs), residing in the promotor region of
a large array of GC-responsive genes. Moreover, the GR can
inhibit gene expression via transrepression that involves binding to
negative GRE sequences or direct binding of the GR to specific
transcription factors such as AP-1 and NF-kB, thereby inhibiting
their potential to stimulate proinflammatory gene expression [1].
The latter mechanism is believed to be importantly involved in
mediating the anti-inflammatory actions of GCs [2].
Tissue responsiveness to GCs under proinflammatory condi-
tions may be modulated by changes in the concentration of
specific cytokines and other extracellular molecules in the tissue’s
microenvironment [3]. Under these circumstances, altered GC
responsiveness may be attributed to induced changes in the tissue’s
ability to regulate its own bioavailability of GC and/or changes in
its GR signaling mechanism. Regarding the former mechanism, it
has been demonstrated in different cell types that various cytokines
can evoke upregulated expression of the endogenous GC-
activating enzyme, 11ß-hydroxysteroid dehydrogenase type 1
(11ß-HSD1), that converts the inactive 11b-oxoglucocorticoid,
cortisone, to its bioactive derivative, cortisol [4–7]. This suggests
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that the localized adverse effects of specific proinflammatory
cytokines may be mitigated by their induced upregulation of 11ß-
HSD1 oxoreductase activity, the latter phenomenon serving an
anti-inflammatory feedback function by facilitating endogenous
GC bioavailability at the affected tissue site. Comparably, GR
function can also be modulated under proinflammatory condi-
tions, as demonstrated by increased GR expression following
exposure of different cell types to proinflammatory cytokines [8–
11], which may confer heighten GC responsiveness. Moreover, the
GR is subject to post-translational modifications that alter its state
of activation and signaling and, conbsequently, the net response to
glucocorticoid exposure.
As a phosphoprotein that is structurally similar to other
members of the superfamily of nuclear receptors, the human
GR is subject to phosphorylation at several serine sites that are
clustered in the N-terminal region containing the transcriptional
activation function-1 (AF1) domain [12,13]. The kinases that
phosphorylate human GR principally include MAPKs, cyclin-
dependent kinases, and glycogen synthase kinase-3 [12–16]. While
hormone binding coupled to GR phosphorylation is critical for
mediating its function, recent evidence demonstrates that the GR
is also susceptible to phosphorylation in the absence of ligand, and
GR hyperphosphorylation can occur when hormone is present
[12,13]. When hyperphosphorylated, the ligand-activated GR
exhibits heightened binding to DNA and, in association with
increased co-factor recruitment, targeted GC-responsive gene
expression is enhanced [13,17]. More recently, significant insight
has been gained into the mechanisms by which GR phosphory-
lation regulates gene transcriptional activity and repression, with
evidence demonstrating that the cluster of phosphorylation sites in
the AF1 domain serve different functions. In the human GR, these
include the serine sites, Ser203, Ser211 and Ser226 that are also
conserved among other species and, largely based on studies
involving mutations at these sites, their relative levels of
phosphorylation were shown to regulate GR localization, co-
factor recruitment, and gene-specific transactivation or transre-
pression [18]. Accordingly, whereas Ser203 phosphorylation has
been associated with nuclear translocation of GR, intra-nuclear
Ser211 phosphorylation was implicated in facilitating GR interac-
tion with the transcriptional co-factor, MED14, and, hence, gene-
specific GR transactivation, while Ser226 phosphorylation was
associated with GR transrepression and enhanced GR nuclear
export [18–20].
In light of the above evidence, and given the important role that
GCs play in suppressing the inflammatory response and altered
airway contractility in asthma [1], this study examined the
regulation of GR signaling in proinflammatory cytokine-stimulat-
ed human airway smooth muscle (HASM) cells. The results are the
first to identify that: 1) HASM cells exposed to the key pro-
asthmatic Th2-type cytokine, IL-13, exhibit ligand-independent
GR activation associated with nuclear translocation coupled to
site-specific GR phosphorylation; and 2) these cytokine-induced
ligand-independent effects confer increased GC hormone-stimu-
lated GR transcriptional activity, thereby serving to homeostati-
cally enhance GC responsiveness. To the extent that this new
evidence suggests that proinflammatory cytokine-induced ligand-
independent GR signaling may importantly contribute to height-
ening GC sensitivity in asthma, future interventions targeted at
this homeostatic signaling mechanism may lead to new approaches
to enhance the efficacy of GC therapy.
Methods
Materials
All chemicals were purchased from Sigma-Aldrich unless
otherwise indicated. The human airway smooth muscle (HASM)
cells were obtained from Bio Whittaker, Inc.
Culture and treatment of ASM cells
HASM cells were grown in SmBm media supplemented with
10% FBS (Bio Whittaker Inc.) and maintained throughout in a
humidified incubator containing 5% CO2 in air at 37uC. The
experimental protocols involved growing the cells to near
confluence in the above medium. Thereafter, in separate studies,
the cells were starved in unsupplemented Ham’s F12 media for
24 hr, and then examined under different experimental conditions
described below.
Assessment of GR translocation
ASM cells were grown on 4-chamber slides to ,85%
confluence. The cells were treated with 100 nM cortisone or
dexamethasone (DEX) for 30 min alone or in combination, both
in the absence and presence of co-treatment with either vehicle or
maximally effective concentrations of either IL-13 (50 ng/ml) or
the combination of IL-1b and TNF-a (10 and 100 ng/ml,
respectively [21,22]. Cells were also treated with either of these
cytokines in absence of hormone exposure. Following treatment,
the cells were fixed with 3.7% formalin to stop the reaction and
then stained for GR using a primary mouse anti-human GRa
antibody and a FITC-conjugated goat-anti-mouse IgG secondary
antibody. Cells were rinsed and then mounted in Vectashield
mounting media with DAPI (Vector Laboratories). An Olympus
IX-81 DSU spinning disk confocal microscope was used to acquire
the images at 606magnification using a 1.49 NA objective. 10–15
cells for each condition were selected for staining clarity, focal
plane uniformity and shape. The majority of the analysis was
derived from images of the cell bodies. Cells were analyzed using
Improvision Volocity classification software (Improvision/Perkin
Elmer), DAPI and FITC area and intensity were measured. Ratio
of intensity of FITC (GR) in the DAPI-stained nuclear area to that
found over the entire cell was calculated. Individual comparative
two-tailed t-tests were conducted to compare the control and
treatment samples.
Transfection of HASM cells with Ser203 and Ser211
phosphorylation-deficient mutant GRs
HASM cells were transfected to over-express either hemagglu-
tinin (HA)-tagged CMV promotor-driven wild-type (WT) human
GR (pCMV-HA-hGR) or the alanine-substituted for serine
phosphorylation-deficient site-specific mutant GRs, pCMV-HA-
hGRS203A (S203A) or pCMV-HA-hGRS211A (S211A) (plasmids
kindly provided by M. Garabedian; NYU, New York, NY). The
transfections are performed using a modified previously described
method [14,25]. Briefly, HASM cells were seeded into 6-well
plates and, at ,40% confluency, the medium was replaced with
the reduced serum-containing medium, Opti-MEM (Invitrogen).
The cells were then transfected with WT or either of the serine
site-specific mutant GR, using Oligofectamine (Invitrogen) as the
transfection agent. Efficiency of transfection was then assessed by
indirect immunofluorescence in cells co-expressing vector-encoded
GFP, and immunoblotting with HA- and GR-specific antibodies.
The efficacy of transfection ranged between 64 and 76%.
Cytokines and Glucocorticoid Receptor Signaling
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Western blot analyses
Confluent HASM cell cultures were serum-starved for 24 hr
and then stimulated with IL-13 or DEX alone and in combination
for varying durations. Cytoplasmic and nuclear fractions of the
cells were then isolated using the NucBuster Protein Extraction Kit
(EMD Biosciences). Equal amounts of proteins (25 mg) were
separated by SDS-PAGE and the extracts were treated with
antibodies at 1:1000 dilution directed against total GRa (BD
Biosciences) and the Ser203- and Ser211-specific phosphorylated
forms of GR (Abcam abd Cell Signaling Technology, respectively).
In comparable experiments, expression of the latter phosphory-
lated forms of GR was also examined in HASM cells that were
transfected with the above WT and mutant S203A and S211A
constructs. Finally, total GR and b-actin protein levels were
detected in WT- and mutant GR-transfected control and IL-13-
treated cells. HRP-conjugated antibody against rabbit IgG was
used as a loading control. The reaction was detected using
enhanced chemiluminescence, and protein band intensities were
quantified by densitometry.
EMSA analysis of GR:DNA binding
HASM cells were starved overnight and then treated for varying
durations with either IL-13 or DEX. As previously described [24],
cell suspensions were then prepared after trypsinization, and
nuclear protein was extracted using the NucBuster Protein
Extraction kit (Novagen). Gel-shift assay was performed using
Panomics EMSA kits that involved incubating the biotin-labeled
GR transcription factor probe or excess unlabelled probe with the
nuclear protein extracts. The mixture was then separated on non-
denaturing polyacrylamide gels and the shifted bands correspond-
ing to the protein/DNA complexes were visualized after exposure
to X-ray film.
Quantitative assessment of GR:DNA binding activity
Nuclear extracts were isolated from control HASM cells and
cells treated for 60 min with varying concentrations of DEX, both
in the absence and presence of pretreatment for 24 hr with either
vehicle alone or IL-13. A sensitive ELISA-based transcription
factor binding assay kit (TransAM) was then used to quantitatively
assess the binding activity of GRa to its consensus DNA sequence
in the nuclear extracts. The protein concentration of each sample
was determined by BCA. Extracts were were incubated in 96-well
plates coated with GR binding consensus oligonucleotide sequence
for 1 h, then incubated with the supplied primary anti-GR
antibody for 1 h, and with a peroxidase-conjugated secondary
antibody for 1 h. After the substrate was added, color development
was read at 450 nm, and the OD of GR was recorded.
GRE-driven transactivation
GR-dependent transcriptional activation was assayed using the
Pathway Profiling System from Clontech (Mountain View, CA), as
previously described [25]. Briefly, after grown to ,85% conflu-
ence, HASM cells were transfected using calcium phosphate with
a vector containing a promoter-reporter construct, pGRE-SEAP,
that is comprised of three glucocorticoid response element (GRE)
sequences upstream from a TATA box and a reporter gene that
encodes a secretable form of alkaline phosphatase (SEAP). Cells
were also transfected with pTAL-SEAP, an identical plasmid but
without the GRE promotor, serving as a negative control, as well
as a plasmid expressing b-galactosidase, (pCMVSport-b-gal)
serving as an internal control. After 18 hours of transfection, the
medium was changed to fresh serum-free Ham’s F-12 media for
8 hours. Cells were then treated for 24 hr either with DEX (1 mM)
or IL-13 (50 ng/ml) under different experimental conditions, as
described. Thereafter, the conditioned culture medium was
harvested and assayed for SEAP activity using the Great EscAPe
SEAP chemiluminescence kit from Clontech, according to the
manufacturer’s protocol.. The measured levels of AP activity were
then normalized to b-galactosidase activity in order to correct for
any variations caused by differences in transfection efficiency
between the cell culture wells.
Co-immunoprecipitation
Co-immunoprecipitation assays were performed under native
conditions in order to preserve protein–protein associations. As
previously described [26], after indicated treatment, cells were
harvested and then lysed with lysis buffer. 1.5 mg of Protein G
Dynabeads (Invitrogen) were incubated with 10 mg of anti-GR
rabbit IgG (Millipore) and incubated for 10 min at room
temperature with rotation. Following several washes, the bound
bead/antibody complex was added to sample, mixed by pipetting,
and incubated for 2 h at 4uC with rotation. The captured bead/
Protein G/antigen complex was washed several times and eluted
at pH 3.0 with rotation at room temperature. The precipitated
immunocomplexes were analyzed by immunoblotting with anti
phospho-GRSer211 and MED14 antibody.
Statistical analyses
Results are presented as means 6 SE or 6 SD values, where
indicated. Comparisons between groups were performed using the
unpaired Student’s t-test or one-way ANOVA, with Tukey-
Kramer post hoc testing, where appropriate. A probability of
,0.05 was considered statistically significant. Statistical analyses
were conducted using the Prism computer program by GraphPad
Software Inc.
Results
Cytokine regulation of ligand-dependent and -
independent GR nuclear translocation in HASM cells
To determine the role of proinflammatory cytokines in
regulating GR signaling in HASM cells, we initially examined
the effects of cytokine exposure on nuclear translocation of the
stimulated GR, a critical feature of GR activation. Confluent
HASM cell cultures were exposed for 30 min to either the
endogenous GC, cortisone (100 nM) or the synthetic GC,
dexamethasone (DEX; 100 nM), both in the absence and presence
of co-treatment with a maximally effective concentration of either
IL-13 (50 ng/ml) or the combination of IL-1b and TNF-a (10 and
100 ng/ml, respectively). The representative photomicrographs in
Fig. 1A depict immunofluorescence staining of GR detected in
cells exposed to either vehicle, cortisone or IL-13 alone, and
cortisone+IL-13; and Fig. 1B displays the corresponding quanti-
tative analysis of the effects of these treatment conditions on
nuclear-to-total cellular fluorescence intensity based on repeated
measurements made in DAPI-stained cells. Relative to the diffuse
cytoplasmic distribution of GR detected in vehicle-exposed
(control) cells (a), cortisone-treated cells exhibited increased intra-
nuclear localization of GR (b); and further markedly enhanced
intra-nuclear GR localization was detected in cortisone-exposed
cells that were co-treated with IL-13 (d). Interestingly, distinctly
increased intra-nuclear localization of GR was also exhibited in
cells that were treated for 30 min with IL-13 alone (c), the latter
observation demonstrating the presence of acute cytokine-induced
ligand-independent nuclear translocation of GR in HASM cells.
Qualitatively, similar induction of hormone-dependent and -
independent nuclear translocation of GR was also detected in
Cytokines and Glucocorticoid Receptor Signaling
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HASM cells that were comparably exposed to either DEX or IL-
1b/TNF-a alone and in combination (Fig. S1). Together, these
observations demonstrate that HASM cells display both GC
ligand-dependent and cytokine-induced ligand-independent nu-
clear translocation of GR, and that these phenomena act
cooperatively whether elicited either by a synthetic or endogenous
GC, and either the Th2 cytokine, IL-13, or the pleiotropic
proinflammatory cytokines, IL-1b and TNFa.
Cytokine regulation of ligand-dependent and -
independent GR phosphorylation and DNA binding
activity
IL-13-induced activation of the unliganded GR was further
substantiated when examining the effects of the cytokine on GR
phosphorylation at its Ser211 residue, which denotes the activated
state of the GR that is largely confined to the nucleus and is
associated with transactivation of GC-responsive genes [16,18,23].
Immunoblot analysis using a mAb that specifically detects Ser211-
phosphorylated GR (p-GRSer211) demonstrated that HASM cells
treated for 1–24 h with IL-13 (50 ng/ml) alone exhibited temporal
increases in p-GRSer211 that were evidenced in the nuclear (N) but
not in the cytoplasmic (C) fraction, with sustained increased
phosphorylation detected at 24 h (Fig. 2A). Moreover, relative to
cells exposed for 60 min to 100 nM of either cortisone or DEX
alone (Figs. 2B and 2C, respectively), distinctly increased p-
GRSer211 was detected in both cortisone- and DEX-exposed cells
that were pretreated with IL-13 (50 ng/ml624 h), and this
enhanced GR phosphorylation was suppressed in cells that were
co-treated with the GR antagonist, RU486 (10 mM). Collectively,
these data demonstrate that, independent of endogenous or
synthetic GC binding to GR, IL-13 elicits nuclear translocation of
the unliganded Ser211-phosphorylated GR and that, in the
presence of either endogenous or synthetic GC ligand, IL-13 acts
cooperatively with the ligand to further enhance intra-nuclear p-
GRSer211 accumulation.
We next investigated whether the cytokine-induced increase in
intra-nuclear bioavailability of the activated GR confers height-
Figure 1. Separate and cooperative effects of DEX-stimulated
and unliganded IL-13-induced nuclear translocation of GR in
HASM cells. GR localization detected by Immunofluorescence staining
(A) and its quantification (B) depicting that, relative to diffuse
cytoplasmic distribution of GR in vehicle-exposed (control) HASM cells
(a), treatment for 30 min with either cortisone (b) or IL-13 alone (c)
elicited increased intra-nuclear localization of GR. which was further
enhanced in cells co-treated with cortisone 6 IL-13 (d). Note: Induced
nuclear translocation of GR by IL-13 alone denotes the presence of
ligand-independent GR activation, and heightened GR translocation
exhibited by cells treated with cortisone 6 IL-13 demonstrates
cooperative effects of ligand (cortisone)-induced and IL-13-induced
ligand-independent GR activation. Data represent mean6SD values
based on an average of 25 HASM cells examined over 3–5 repeats
(*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0060452.g001
Figure 2. Immunoblot analysis of separate and combined
effects of ligand-stimulated and unliganded IL-13-induced
GRSer211 phosphorylation in HASM cells. (A) Treatment with IL-
13 elicits progressive increases in p-GRSer211 for up to 24 h following
cytokine exposure that are detected in the nuclear (N) and not the
cytoplasmic (C) fraction. Induction of p-GRSer211 by cortisone (B) or DEX
(C) is increased in HASM cells initially exposed for 24 h to IL-13; and the
p-GRSer211 response is markedly suppressed in cells pretreated with the
GR antagonist, RU486.
doi:10.1371/journal.pone.0060452.g002
Cytokines and Glucocorticoid Receptor Signaling
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ened ligand-independent and/or hormone-stimulated downstream
GR signaling. As shown in Fig. 3A, using EMSA to detect GR
binding to its consensus DNA sequence (GRE), contrasting the
expected acute progressive induction by DEX (1 mM) of GR
binding to DNA over 60 min, HASM cells treated with IL-13
alone (50 ng/ml) did not exhibit induced GR:DNA binding
activity. By comparison, as shown in Fig. 3B, when evaluating
whether pretreatment with IL-13 alters DEX-stimulated GR:DNA
binding activity, the latter quantitatively assessed using a highly
sensitive ELISA assay, relative to control (vehicle-treated) cells,
dose-dependent stimulation of GR:DNA binding activity by DEX
was significantly increased in HASM cells that were pretreated
with IL-13 (50 ng/ml624 h). Taken together, these results
demonstrate that, although IL-13 can independently evoke
translocation and intra-nuclear accumulation of p-GRSer211, this
unliganded ‘‘early’’ GR activation by IL-13 does not confer GR
interaction with DNA but, rather, the response to IL-13 serves to
heighten HASM sensitivity to hormone-stimulateed GR:DNA
binding activity. In light of this evidence, a series of studies were
pursued to elucidate the potential mechanism underlying IL-13-
induced enhanced GC ligand-dependent GR activation, and
determine whether this mechanism enables heightened GR
transactivation.
IL-13-induced regulation of unliganded and ligand-
dependent GR phosphorylation and transactivation
Whereas the intra-nuclear presence of p-GRSer211 was shown to
denote the hormone-activated state of GR, intra-cytoplasmic
phosphorylation of GRSer203 has also been demonstrated in the
presence of GC ligand, and a potential interdependence of
phosphorylation at these serine sites has been proposed [23]. To
test whether HASM cells exhibit such interdependence in GR
phosphorylation in the presence of ligand-dependent and -
independent GR stimulation, anti-p-GRSer203- and anti-p-
GRSer211-specific antibodies were used to initially determine the
kinetics of GR phosphorylation at these serine sites in HASM cells
that were treated for up to 24 h with either DEX or IL-13 alone
and in combination. The representative immunoblots and
corresponding densitometric analysis of immunoreactivity shown
in Fig. 4A demonstrate that relatively little p-GRSer211 was
detected in the absence of ligand and that treatment with DEX
elicited an early acute increase in p-GRSer211, wherein the level of
immunoreactivity peaked at ,2.5-fold above baseline at 0.5 h
(mean = 2.9760.64-fold in n = 4 experiments; p,0.05) and
progressively decreased thereafter, but remained elevated above
baseline at 24 h. By comparison, while distinctly present in the
absence of ligand, GRSer203 phosphorylation did not notably
change following DEX administraion. Contrasting these responses
to DEX, as shown in Fig. 4B, HASM cells treated with IL-13
alone exhibited an early progressive increase in p-GRSer203 that
peaked at 3 h (mean = 2.360.52-fold; p,0,05) and gradually
declined thereafter, whereas p-GRSer211 increased progressively
after 1 h, with enhanced sustained phosphorylation at 24 h
peaking at ,2.0-fold (mean = 2.3960.49-fold; p,0.05). By
comparison, as shown in Fig. 4C, cells exposed to DEX+IL-13
displayed an early increase in p-GRSer203 and, contrasting the
transient response to DEX treatment alone, elevated p-GRSer211
levels were sustained by 24 h (mean = 3.4760.68-fold; p,0.05). In
relation to these observations, it will be noted that total GR protein
(GRtotal) expression was unaffected by IL-13 exposure alone and,
while treatment with DEX, either alone or in combination with
IL-13, had little effect initially, GRtotal levels progressively
decreased after ,2 h to a nadir averaging 55.965.8% of baseline
at 24 h in DEX6IL-13-treated cells. This reduction in GR
expression in DEX-exposed cells, but not in unliganded cells
treated with IL-13 alone, is consistent with the well documented
observation that the GR undergoes down-regulation following
ligand exposure, a finding reportedly attributed to enhanced GR
mRNA and protein turnover in the continued presence of
hormone [26,27].
To next examine whether the above IL-13-induced temporal
changes in site-specific GR phosphorylation are causally related,
the effects of IL-13 on peak GRSer203 and GRSer211 phosphory-
lation, determined at 3 and 24 h, respectively, were assessed in
HASM cells that were transfected to overexpress hemagglutinin
(HA)-tagged CMV promotor-driven wild-type human GR
(pCMV-HA-hGR) and either of the alanine-substituted for serine
site-specific mutant GRs, pCMV-HA-hGRS203A (S203A) or
pCMV-HA-hGRS211A (S211A) (plasmids kindly provided by M.
J. Garabedian; NYU, New York, NY). Immunoblotting using anti-
HA- and anti-GR-specific antibodies demonstrated that, under
similar loading conditions, as evidenced by the same level of
GRtotal detected with anti-HA antibody (Fig. 5A): 1) unlike in non-
transfected (control) and wild-type (WT) GR-transfected cells
wherein IL-13 elicited increases in both p-GRSer203 and p-
GRSer211, minimal p-GRSer211 was detected in IL-13-exposed
S203A mutant transfected cells; and 2) by comparison, as in
control and WT cells, IL-13-induced upregulation of p-GRSer203
Figure 3. Comparison of DNA binding activity of GR in HASM
cells exposed to either DEX or IL-13 alone and in combination.
(A) EMSA depicting that GR binding to its consensus DNA sequence is
acutely elicited by ligand stimulation with DEX, whereas treatment with
IL-13 alone does not evoke GR:DNA binding. (B) Following 24 h
exposure to vehicle alone (control), HASM cells treated with DEX exhibit
dose-dependent stimulation of GR:DNA binding activity, the latter
quantified using a sensitive ELISA kit. GR:DNA binding activity is
significantky increased at all administered doses of DEX in cells
pretreated for 24 h with IL-13. Data are mean 6 SE values based on
4–5 determinations at each administered dose of DEX. *p,0.05.
doi:10.1371/journal.pone.0060452.g003
Cytokines and Glucocorticoid Receptor Signaling
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was distinctly present in cells transfected with S211A mutant
construct. The observation that IL-13-induced GRSer211 phos-
phorylation is suppressed in cells transfected with the S203A
construct suggests that the above depicted initial phosphorylation
of GRSer203 by IL-13 (Fig. 4B) is needed to enable subsequent GR
phosphorylation at Ser211. Thus, these data are consistent with an
earlier report implicating the presence of interdependence of GR
phosphorylation at the serine 203 and 211 sites [23]. Of note,
Figure 4. Comparison of induced temporal changes in site-specific GR phosphorylation in HASM cells treated with DEX or IL-13
alone and in combination. Representative immunoblots from one of three experiments depicting that, nder basal conditions, relative to p-
GRSer211, HASM cells exhibit distinctly increased p-GRSer203 levels. Contrasting the acute transient increase in p-GRSer211 elicited by DEX treatment
alone (A), HASM cells treated with IL-13 alone exhibit an initial increase in p-GRSer203 followed by a progressive increase in p-GRSer211 (B), whereas
combined treatment with DEX+IL-13 evokes sustained increases in p-GRSer203 and p-GRSer211 for up to 24 h (C). Note, GRtotal levels are unaffected in
HASM cells exposed to IL-13. By comparison, cells treated with DEX (alone or in combination with IL-13) exhibit progressive decreases in GRtotal levels.
doi:10.1371/journal.pone.0060452.g004
Cytokines and Glucocorticoid Receptor Signaling
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comparable experiments demonstrated that, unlike with IL-13,
DEX-induced GRSer211 phosphorylation, which is not associated
with initial GRSer203 phosphorylation (Fig. 4A), was unaffected by
transfection with the S203A mutant (data not shown).
Given the above evidence of interdependence of GR phos-
phorylation at its serine 203 and 211 sites in IL-13-exposed cells,
we reasoned that the sustained heightened GRSer211 phosphory-
lation exhibited in cells treated with DEX+IL-13 (Fig. 4C) likely
accounts for the increased DEX-induced GR:DNA binding
activity detected in the presence of IL-13 (Fig. 3B). Accordingly,
we next examined whether the latter effect of IL-13 confers
enhanced hormone-stimulated GR transcriptional activity. As
previously described (25), GR transactivation was assessed in
HASM cells transfected with a promoter-reporter construct
comprising a secretory alkaline phosphatase (SEAP) reporter
driven by a GRE-dependent promoter (pGRE-SEAP). The
transfected cells were treated with IL-13 (50 ng/ml) or DEX
(1 mM) alone and in combination and, 24 h thereafter, the culture
media was assayed by chemiluminescence for SEAP activity
attributed to GR transactivation. As shown in Fig. 5B, contrasting
the lack of effect of treatment with IL-13 alone, SEAP activity was
significantly increased in HASM cells exposed to DEX, and this
stimulatory effect of DEX was significantly enhanced in cells co-
treated with IL-13, in concert with the above observed increased
GR:DNA binding activity (Fig. 3B) associated with hyperpho-
sphorylation of GRSer211 in DEX+IL-13-treated cells (Figs. 2C
and 4). This IL-13-induced heightened hormone-stimulated GR
transcriptional activation was prevented in IL-13-exposed that
were transfected with the S203A mutant, wherein SEAP activity
was similar to that detected in cells exposed to DEX alone. Not
surprisingly, given the known critical role of Ser211 phosphory-
lation in mediating hormone-stimulated GR transactivation,
induction of SEAP activity by DEX was suppressed in HASM
cells transfected with the S211A mutant construct (Fig. 5B).
MAPK activation mediates effects of IL-13 on DEX-
induced GR transcriptional activity
The pro-asthmatic effects of IL-13 in HASM cells were
previously shown to be largely mediated by MAPK signaling,
specifically involving IL-13-induced acute ERK1/2 and JNK
activation [25,28,29]. Given this evidence, together with that
demonstrating that MAPK activation regulates GR phosphoryla-
tion in various cell types [13–15], the potential role of MAPK
signaling in regulating IL-13-induced changes in GR phosphor-
ylation and its transcriptional activity in HASM cells was
examined both in the absence and presence of hormone
stimulation. Initial studies investigating the effects of specific
MAPK inhibitors on IL-13-induced phosphorylation of GRSer203
and GRSer211 demonstrated that the peak increases in both p-
GRSer203 and p-GRSer211 detected at 3 and 12 hr following IL-13
administration, respectively (Fig. 4), were inhibited in HASM cells
pretreated with either the MEK-ERK1/2 inhibitor, U0126
(5 mM), or the JNK inhibitor, SP600125 (10 mM), whereas the
p38 MAPK inhibitor, SB202190 (10 mM), had no inhibitory effect
(Fig. 6A). Subsequent examination of the effects of these inhibitors
on GRSer211 phosphorylation in cells exposed to IL-13 in the
absence and presence of hormone stimulation demonstrated that,
relative to the increases in p-GRSer211 phosphorylation elicited in
cells treated with either IL-13 (50 ng/ml624 h) or DEX
(1 mM61 h) alone, the hyperphosphorylation of GRSer211 detected
in DEX+IL-13-exposed cells was abrogated by pretreatment with
either the ERK1/2 or JNK inhibitor, whereas the p38 MAPK
inhibitor had no appreciable effect (Fig. 6B). Similar results to
those exemplified in Figs. 6A and 6B were obtained in additional
experiments, as demonstrated by quantitative densitometric
analysis of the fold-changes in p-GRSer203 and p-GRSer211
expression detected under the same treatment conditions (Fig.
S2). Moreover, these results were comparable to those obtained
when using the SEAP reporter assay to assess the effects of these
treatment conditions on GR transcriptional activity (Fig. 6C).
Accordingly, in concert with its aforementioned lack of effect on
GR:DNA binding activity (Fig. 3A), IL-13 treatment alone had no
significant effect on SEAP activity. By comparison, as expected,
SEAP activity was significantly increased in cells exposed to DEX;
Figure 5. Interdependence of IL-13-induced GRSer203 and
GRSer211 phosphorylation in HASM cells: Role in regulating
GR tranactivation. (A) Immunoblots using anti-HA- and anti-GR
phosphorylation-specific antibodies comparing the effects of IL-13 on
GRSer203 and p-GRSer211 phosphorylation in HASM cells transfected with
wild-type (WT) and either Ser203 or Ser211 phosphorylation-deficient
mutant GR (S203A or S211A). Note: Under similar loading conditions,
given by comparable levels of GRtotal detected with anti-HA antibody,
IL-13-induced increase in GRSer211 phosphorylation is prevented in
HASM cells transfected with the S203A mutant GR, whereas phosphor-
ylation of GRSer203 by IL-13 is unaffected in cells transfected with the
S211A mutant construct (B) Comparison of effects of IL-13 on DEX-
induced GR transactivation, detected using the SEAP reporter assay, in
control HASM cells and cells transfected with either the S203A or S211A
phosphorylation-deficient mutant GR. Note: Contrasting the lack of
effect of IL-13 alone, SEAP activity is significantly increased in DEX-
treated cells, and the response to DEX is significantly enhanced in the
presence of IL-13. The latter stimulatory effect of IL-13 on DEX-induced
GR transactivation is abrogated in cells transfected with the S203A
mutant construct, and GR transactivation by DEX is prevented in cells
transfected with the S211A mutant GR. Data represent mean 6 SE
values from 4–5 experiments (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0060452.g005
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and the stimulatory effect of DEX was significantly enhanced in
cells co-treated with IL-13, in accordance with both the
corresponding hyperphosphorylation of GRSer211 (Fig. 6B) and
heightened GR:DNA binding activity detected in DEX+IL-13-
exposed cells (Fig. 3B). The augmented hormone-stimulated
transcriptional activity was abrogated by pretreating DEX+IL-
13-exposed cells with either the ERK1/2 or JNK inhibitor,
whereas the p38 MAPK inhibitor had no effect. Collectively, these
data are consistent with the notion that, while having no effect
alone on GR:DNA binding activity, IL-13 enhances hormone-
stimulated GR transcriptional activity due to hyperphosphoryla-
tion of GRSer211 that is attributed to IL-13-induced activation of
the GR, associated with MAPK-dependent GRSer203 phosphory-
lation, which upregulates ligand-stimulated GRSer211 phosphory-
lation.
The above notion was further substantiated in co-immunopre-
cipitation experiments wherein the effects of the MAPK inhibitors
on IL-13-induced changes in hormone-stimulated recruitment of
MED14, the transcriptional co-factor associated with GR
hyperphosphorylation coupled to heightened transactivation
[13,18], were examined in DEX-exposed HASM cells. The
immunoblots (IB) in Fig. 7A demonstrate that, relative to
unstimulated cells, increased co-localization of both phosphory-
lated GRSer211 and MED14 with immunoprecipitated (IP) GR was
detected in nuclear extracts from HASM cells exposed to either
IL-13 or DEX alone, and this co-localiztion was further enhanced
in IL-13+DEX-treated cells. The latter heightened co-localization
was largely abrogated in IL-13+DEX exposed cells that were
pretreated with either U0126 or SP600125, implicating regulatory
roles for ERK1/2 and JNK activation, respectively, whereas the
p38 MAPK inhibitor had no effect. Of note, the above observed
effects were detected in the absence of any corresponding changes
in total MED14 protein expression under the same treatment
conditions (Fig. 7B). Thus, together with the above observations,
these data support the concept that IL-13-regulated heightened
phosphorylation of the hormone-stimulated GR, coupled to
recruitment of MED14 to the hyperphosphorylated GR, is
reponsible for the increased DEX-stimulated GR transcriptional
actvity exhibited in the presence of the cytokine.
Discussion
The bronchoprotective action of GCs in asthma therapy is not
only due to their anti-inflammatory properties but also reflects
their ability to directly act on ASM by inhibiting its contractility,
increasing its relaxation, inhibiting ASM cell proliferation,
preventing the release of various proinflammatory cytokines and
chemokines from the pro-asthmatic sensitized ASM, and addi-
tional actions [22,30,31]. As in other tissues, an important
determinant of ASM responsiveness to endogenous and a variety
of synthetic GCs is its ability to regulate pre-receptor GC
bioavailability by modulating the activities of the GC-activating
and -inactivating isozymes, 11ß-HSD1 and HSD2, respectively
[25,32]. Accordingly, exposure of HASM cells to proinflammatory
cytokines (e.g., IL-13, IL-1b/TNFa, etc) was shown to upregulate
11ß-HSD1 and inhibit 11ß-HSD2 expression, thereby allowing for
increased conversion of cortisone into its bioactive derivative,
cortisol [22,25,32,33], which serves to homeostatically suppress the
opposing pro-asthmatic effects of the cytokine on airway
contractility [25,32]. The present study sought to determine
whether the homeostatic response of HASM to proinflammatory
cytokine exposure also includes changes in GR signaling by
exploring unliganded and ligand-dependent GR activation in
HASM cells stimulated by the key pro-asthmatic cytokine, IL-13.
The results are the first to demonstrate that: 1) IL-13-exposed
HASM cells exhibit ligand-independent activation of the GR that
involves its nuclear translocation coupled to MAPK-regulated
sequential phosphorylation of GR at its serine 203 and 211 sites;
and 2) this cytokine-driven unliganded GR response confers
Figure 6. GR phosphorylation by IL-13 and its induction of
heightened DEX-stimulated GRSer211 phosphorylation and
transactivation are suppressed by inhibition of ERK1/2 and
JNK signaling. (A) Representative immunoblots from one of three
experiments demonstrating that IL-13-induced maximal GRSer203 and
GRSer211 phosphorylation elicited at 3 and 12 h, respectively, are
suppressed in HASM cells pretreated with either the ERK1/2 or JNK
inhibitors, U0125 and SP600125, respectively, whereas pretreatment
with the p38 MAPK inhiobitor, SB202190, has no appreciable effect.
Comarably, heightened DEX-stimulated GRSer211 phosphorylation (B)
and transactivation of SEAP activity (C) exhibited in IL-13-exposed
HASM cells are suppressed by pretreatment with the ERK1/2 and JNK
inhibitors, whereas the p38 MAPK inhiobitor has no effect. Data are
mean 6 SE values from 4 experiments (*p,0.05; **p,0.01).
doi:10.1371/journal.pone.0060452.g006
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increased GC hormone-stimulated GRSer211 phosphorylation and
DNA binding activity that, in association with enhanced
recruitment of the co-factor, MED14, to the hyperphosphorylated
GR, allows for heightened GR transactivation. Together, these
novel findings highlight a heretofore unidentified homeostatic
cytokine-driven GR signaling mechanism in HASM that involves
ligand-independent GR activation which enables increased
responsiveness to GC hormone treatment. This intrinsic homeo-
static mechanism may serve an important role by enhancing the
efficacy of GC therapy in mitigating the airway asthmatic
response.
A number of previous studies have demonstrated the presence
of ligand-independent activation of steroid receptors in different
cell types, including the estrogen [34,35], progesterone [36], and
androgen [37] receptors, and there is now emerging evidence that
also implicates ligand-independent activation of the GR. In this
regard, stimulation of lung fibroblasts and vascular smooth muscle
cells with b2-adrenoceptor agonists was shown to evoke ligand-
independent GR activation [38], and unliganded GR activation
was also demonstrated in ursodeoxycholic bile acid-treated
hamster ovary cells [39], LbT2 and COS-1 cells stimulated with
gonadotropin-releasing hormone (GnRH) [40], and TNFa treat-
ment of a human endocervical epithelial cell line. End1/E6E7,
and COS-1 cells [41]. In general agreement with this recent
evidence, our present observations demonstrate that proinflam-
matory cytokine-exposed HASM cells exhibit acute nuclear
translocation coupled to phosphorylation of the unliganded GR.
These data raise certain noteworthy issues. First, in demonstrating
that GR translocation was elicited in HASM cells that were
exposed to either the Th2 cytokine, IL-13, or the pleitropic
cytokines, IL-1b and TNFa, our results imply that the induced
unliganded GR response is not cytokine-specific, as least with
respect to the latter proinflammatory cytokines (discussed below).
Secondly, to the extent that the magnitude of intra-nuclear
immunofluorescence staining of GR detected in HASM cells
treated with IL-13+DEX was roughly comparable to the additive
effects of IL-13 and DEX alone (Fig. 1), these data demonstrate
that the responses to ligand-dependent and -independent GR
activation are not mutually exclusive but, rather, appear synergis-
tic in nature. This notion was further substantiated by the
observation that intra-nuclear accumulation of phosphorylated
GRSer211, which denotes the activated state of the receptor, was
distinctly increased in IL-13+hormone (cortisone or DEX)-treated
HASM cells relative to cells exposed to hormone alone (Fig. 2). In
this regard, it should be noted that the increased phosphorylated
GRSer211 detected in IL-13+hormone-stimulated cells denoted the
presence of heightened GR activation as this response was
inhibited by pretreatment with RU486, a well characterized GR
antagonist that has a high affinity for the receptor [42].
Post-translational modification of GR is known to regulate
various aspects of GR signaling including its nuclear translocation,
co-factor recruitment, DNA binding activity, and transactivation
or transrepression functions. In addition to Ser211 phosphoryla-
tion, key sites for such covalent modification of the human GR in
the AF1 region include residues Ser203 and Ser226 [13,16,18].
Whereas Ser226 phosphorylation has been associated with
attenuated GR signaling and transcriptional repression
[18,20,23,41,43], Ser203 phosphorylation is preferentially retained
in the cytoplasm and has been implicated in regulating hormone-
stimulated Ser211 phosphorylation, resulting in increased GR
transcriptional activity [18,23]. The latter interdependence of GR
phosphorylation was also demonstrated herein when examining
the effects of IL-13 on unliganded and DEX-stimulated GR
phosphorylation, GR:DNA binding activity, and transcriptional
activation. In this connection, the results demonstrated that IL-13
alone elicits sequential GR phosphorylation, initially at Ser203
followed by progressive and sustained Ser211 phosphorylation
(Fig. 4B), and that these temporal patterns of site-specific GR
phosphorylation are causally related, as evidenced by abrogation
of IL-13-induced Ser211 phosphorylation in HASM cells that are
transfected with the S203A mutant construct (Fig. 5A). While this
observation concurs with earlier evidence demonstrating an
interdependece of Ser203 and Ser211 phosphorylation in other cell
types (23), it should be noted that our observed unliganded p-
GRSer203 -dependent phosphorylation of GRSer211 in IL-13-
exposed HASM cells was not accompanied by changes in either
GR:DNA binding activity or GR transactivation. Rather, expo-
sure to IL-13 was found to enhance hormone-stimulated GR
signaling, as demonstrated by sustained augmented GRSer211
hyperphosphorylation, increased GR:DNA binding activity, and
heightened GR transactivation in DEX+IL-13-exposed HASM
cells, as compared to the corresponding responses exhibited in cells
treated with DEX alone. Moreover, in concert with the observed
suppression of IL-13-induced Ser211 phosphorylation in cells
transfected with the S203A mutant (Fig. 5A), the heightened GR
transactivation detected in IL-13+DEX-exposed cells was also
curtailed in cells transfected with the phosphorylation-deficient
S203A mutant construct (Fig. 5B). Thus, given the different
temporal patterns of serine site-specific GR phosphorylation,
together with the lack of induced GR:DNA binding activity and
GR transactivation, the mechanism of IL-13-stimulated unli-
ganded GR activation appears to be qualitatively different from
Figure 7. Enhanced DEX-induced co-localization of p-GRSer211
and the transcriptional co-factor, MED14, in IL-13-exposed
HASM cells is prevented by inhibition of ERK1/2 and JNK
signaling. (A) Representative co-immunoprecipitation study demon-
strating increased co-localization of both phosphorylated GRSer211 and
MED14, detected by immunoblotting (IB), with immunoprecipitated (IP)
GR in nuclear extracts from HASM cells exposed to either IL-13 or DEX
alone. The latter co-localiztion is further enhanced in IL-13+DEX-treated
cells, and is largely suppressed by pretreating the cells with either the
ERK1/2 or JNK inhibitor, whereas the p38 MAPK inhibitor has no effect.
(B) Note: The above effects elicited under the different treatment
conditions are detected in the absence of any corresponding change in
total MED14 protein expression.
doi:10.1371/journal.pone.0060452.g007
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that elicited by hormone exposure alone in HASM cells.
Nevertheless, although arguably different, the mehanisms regulat-
ing the unliganded and ligand-induced GR responses act
synergistically to heighten the net hormone-stimulated GR
transcriptional response.
When evaluated in light of recent reports, the present results
raise certain relevant considerations regarding the phenomenon of
unliganged GR signaling. In this respect, whereas our observations
in IL-13-exposed HASM cells are consistent with the finding of
acute nuclear translocation of the non-ligand-stimulated GR in
other cell types [38,39,41], we found no evidence that this early
IL-13-stimulated signaling event is associated with altered
GR:DNA binding activity or GR-regulated transactivation. This
contrasts with the reported observations that unliganded GR
activation is accompanied by induced GR:DNA binding and
transactivation in various cell types including b2-adrenoceptor-
stimulated lung fibroblasts and vascular smooth muscle cells [38],
ursodeoxycholic-treated hamster ovary cells [39], and LbT2 and
COS-1 cells stimulated with GnRH [40]. While this disparity is
not readily explained, apart from differences potentially related to
cell type, GRa isoform-specific activation, post-translational GR
modifications, and other factors, consideration must also be given
to the specific experimental conditions used to elicit unliganded
GR activation. This issue is exemplified when comparing our
present observations involving proinflammatory cytokine exposure
in HASM cells to those recently reported using TNFa in End1/
E6E7 and COS-1 cells, wherein treatment with the cytokine was
found to induce phosphorylation of the unliganded GR at Ser226
(and not at Ser211) which, along with recruitment of the GR co-
factor, GRIP-1, was required for ligand-independent repression of
IL-6 expression in response to TNFa [41]. By comparison, our
data demonstrated that IL-13 elicits ligand-independent MAPK-
mediated GRSer203 phosphorylation that evokes Ser211 phosphor-
ylation of the unliganded GR, and that this covalent modification
is heightened in the presence of hormone stimulation in
association with increased recruitment of MED14 to the
hyperphosporylated GR, and consequent increased hormone-
stimulated GR:DNA binding activity and transactivation. Of note,
the latter mechanistic scenario fundamentally agrees with that
proposed in an earlier study demonstrating that steroidogenic
factor 1 (SF-1), a nuclear receptor that regulates many peptide
hormone-induced genes, also exhibits ligand-independent MAPK-
mediated phosphorylation of SF-1 at its Ser203 residue in the AF1
region, which facilitates co-factor recruitment that then confers
coordinated regulation of multiple SF-1 target genes in response to
hormone stimulation [44].
In view of earlier studies demonstrating that the pro-asthmatic
effects of IL-13 in HASM cells are largely attributed to MAPK
activation [24,28,29], and given our recent finding that acute
activation of the MAPKs, ERK1/2 and JNK, mediates IL-13-
induced upregulation of the GC-activating enzyme, 11b-HSD1 in
HASM cells [24], the potential role of MAPK activation in
regulating IL-13-induced GR signaling was examined herein. Our
results demonstrated that inhibition of ERK1/2 and JNK
activation suppressed the stimulatory effects of IL-13 on GR
signaling, including the early and subsequent IL-13-induced
phosphorylation of GRSer203 and GRSer211, respectively, as well
as the hyperphosphorylation of GRSer211 and heightened GR
transactivation accompanying increased recruitment of MED14 to
the GR in DEX+IL-13-exposed cells. Taken together, these data
are consistent with the important role previously attributed to
MAPK activation (notably ERK1/2 and JNK) in regulating
hormone-stimulated GR phosphorylation and its transcriptional
response in other cell types [13,18,19,45,46], as well as unliganded
GR phosphorylation by GnRH in the LbT2 cell line [40]. This
evidence notwithstanding, it remains to be established whether our
observations additionally reflect, at least in part, the contributions
of other kinases that are also known to regulate human GR
phosphorylation, including cyclin-dependent kinases and glycogen
synthase kinase-3 [13].
The nature of the interaction between proinflammatory
cytokines and GR signaling is complex and often viewed as
mutually antagonistic, with studies reporting attenuated GR
function in isolated peripheral blood mononuclear cells (PBMCs)
exposed to proinflammatory cytokines and in PBMCs isolated
from steroid-resistant asthmatic individuals [47–50]. Specifically,
regarding the action of IL-13, it was previously reported that the
suppressive effect of hydrocortisone on LPS-induced IL-6
production is significantly attenuated in IL-13-treated human
monocytes, and that this suppressive effect is attributed to IL-13-
induced reduction in GR binding affinity [50]. Conversely, other
studies have reported an increase in GR expression under different
proinflammatory conditions and following treatment of different
cell lines, including airway epithelial cells, with proinflammatory
cytokines [8–11]. While these seemingly discordant previous
findings are not easily reconciled, they may be reflective (at least
partially) of the effects of specific cytokine treatments on hormone-
stimulated GR signaling. This notion is evidenced when consid-
ering the findings in recent studies that examined the effects of
different cytokine treatments on GC responses in HASM cells.
Accordingly, whereas treatment of HASM cells with the combi-
nation of TNFa and IFNc was recently shown to inhibit GRSer211
phosphorylation by the GC ligand, fluticasone, presumably due to
increased phosphatase-specific activity [51], it was previously
reported that, unlike with TNFa and IFNc, suppression of GC
action in HASM cells was not seen with the treatment
combinations of TNFa and either IL-1b or IL-13 [52]. Although
the latter studies did not examine the unliganded effects of
cytokine stimulation alone, given that our present observations
demonstrate that IL-13 and combined treatment with TNFa+IL-
1b elicit cooperative ligand-independent and -dependent stimula-
tory effects on GR activation, it appears that, even within the same
cell type, the effects of cytokine stimulation on GC responsiveness
are selective to certain cytokines or their combination. This issue
emphasizes the need for future in depth studies to address the
interactions between individual and combined cytokine treatments
and GR signaling.
In conclusion, this study examined the effects and mechanisms
of action of pro-asthmatic cytokine exposure in regulating both
ligand-independent and -dependent GR signaling in HASM cells.
The data are the first to demonstrate that: 1) HASM cells exposed
to IL-13 exhibit ligand-independent GR activation that involves its
nuclear translocation and MAPK-mediated sequential serine site-
specific phosphorylation, coupled to recruitment of the MED14
co-factor to the unliganded phosphorylated GR; and 2) this
unliganded GR activation enables heightened hormone-stimulated
GR signaling in the cytokine-exposed HASM cells wherein
increased GR translocation and GRSer211 phosphorylation confers
emhanced hormone-stimulated GR:DNA binding, recruitment of
MED14, and transactivation. Thus, these data highlight a
heretofore unidentified pro-asthmatic cytokine-driven homeostatic
GR siganling mechanism in HASM cells that serves to heighten
GC hormone responsiveness, as schematically depicted in Fig. 8.
This new evidence, when considered in light of the challenge faced
in treating a significant number of severely asthmatic individuals
that are insensitive to GC therapy, raises the consideration that
this GC insensitivity may be related, at least in part, to
perturbations in the herein-described homeostatic cytokine-driven
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GR signaling mechanism. This possibility warrents systematic
investigation since, if confirmed, it may lead to the development of
future interventions targeted at such perturbations in GR
signaling, thereby potentially enhancing the efficacy of GC
treatment of asthma.
Supporting Information
Figure S1 Separate and combined effects of dexameth-
asone (DEX) and IL-b/TNFa on nuclear translocation of
GR in HASM cells. GR localization detected by immunofluo-
rescence staining demonstrates that, relative to diffuse cytoplasmic
distribution of GR in vehicle-exposed (control) HASM cells,
treatment for 30 min with either DEX or IL-b/TNFa alone elicits
increased intra-nuclear localization of GR. which appears further
enhanced in cells co-treated with DEX 6 IL-b/TNFa.
(TIF)
Figure S2 Densitometric analysis of immunoblots de-
picting that GR phosphorylation by IL-13 and its
induction of heightened DEX-stimulated GRSer211 phos-
phorylation are suppressed by inhibition of ERK1/2 and
JNK signaling. (A) IL-13-induced increases in maximal levels of
p-GRSer203 and p-GRSer211 detected at 3 and 12 h, respectively,
expressed as fold-changes from baseline, are suppressed in HASM
cells pretreated with either U0125 or SP600125, whereas
pretreatment with SB202190 has no significant effect. (B)
Similarly, increased levels of DEX-stimulated p-GRSer211 in IL-
13-exposed HASM cells are suppressed by pretreatment with the
ERK1/2 and JNK inhibitors, whereas the p38 MAPK inhibitor
has no effect. Data are mean 6 SE values from n = 4 experiments
under each treatment condition (*p,0.05).
(TIF)
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Figure 8. Schematic representation of proposed homeostatic mechanism involving cytokine-stimulated ligand-independent GR
activation and its induction of heightened ligand-stimulated GR signaling and transactivation. Cytokine (IL-13) exposure acutely elicits
ERK1/2- and JNK-mediated GRSer203 phosphorylation that leads to p-GRSer203-dependent GRSer211 phosphorylation. The dual GRSer203/211
phosphorylated state is transient, as Ser203 becomes dephosphorylated (unidentified phosphatase (13)) and p-GRSer211 translocates to the nucleus
where it associates with the transcriptional co-factor, MED14. In the absence of hormone, the unliganded p-GRSer211-MED14 complex is incapable of
binding to DNA. With hormone exposure, ligand entering the cell can translocate to the nucleus both as free and GR-bound ligand, the latter leading
to GRSer211 phosphorylation potentially via the kinase activities of cyclin-dependent kinase (CDK) or glycogen synthase kinase-3 (GSK-3). Note: relative
to ligand treatment alone, combined cytokine+ligand exposure elicits increased intra-nuclear levels of p-GRSer211 coupled to MED14, leading to
heightened GR transcriptional activity upon recruitment of free ligand to the cytokine-stimulated unliganded p-GRSer211-MED14 complex.
doi:10.1371/journal.pone.0060452.g008
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